Literature DB >> 26834969

A review of the management of antidepressant discontinuation symptoms.

Emma Wilson1, Malcolm Lader2.   

Abstract

Strong evidence supports the existence of a discontinuation syndrome following the withdrawal of antidepressant medication, particularly second-generation antidepressants. The syndrome is a common phenomenon and guidance as to best avoid the symptoms is essential for both practitioners and patients. The current study reviewed the available literature on the best methods of discontinuation for antidepressants in order to avoid or prevent the occurrence of any unpleasant side effects associated with antidepressant withdrawal. Accordingly, an electronic search of the PubMed/MedLine database and Google Scholar was conducted to find relevant literature published within the last 10 years. From this, 18 related articles were identified; five clinical studies, one case series, one consensus panel's recommendations and 11 literature reviews. Of the articles reviewed there is a general consensus as to tapering the drug slowly over a period of weeks or months. Also, in those patients who experience severe symptoms the drug should be reinstated and discontinued more gradually. The discontinuation syndrome does not occur as frequently or severely with longer-acting agents such as fluoxetine and therefore it is recommended that switching to this drug prior to withdrawal may be advisable. The articles reviewed also emphasize the need for patient education and reassurance throughout the discontinuation process. One in particular adds that cognitive behavioural therapy may be a useful tool in easing the patients' distress. However, this review highlights the lack of controlled data to support the available guidelines. Furthermore, the guidance which is available is somewhat conflicting. Research approaches should address this issue as well as develop appropriate methods of withdrawal for specific drugs.

Entities:  

Keywords:  antidepressant medication; discontinuation syndrome; gradual dose tapering

Year:  2015        PMID: 26834969      PMCID: PMC4722507          DOI: 10.1177/2045125315612334

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  41 in total

1.  Cognitive behaviour therapy for withdrawal from antidepressant medication: a single case series.

Authors:  Paul Cromarty; Jaime Jonsson; Steve Moorhead; Mark H Freeston
Journal:  Behav Cogn Psychother       Date:  2010-09-20

2.  Gradual dose reduction and medication tapering: a clinical perspective.

Authors:  Manju T Beier; Caren McHenry Martin
Journal:  Consult Pharm       Date:  2007-08

Review 3.  Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research.

Authors:  Alan F Schatzberg; Pierre Blier; Pedro L Delgado; Maurizio Fava; Peter M Haddad; Richard C Shelton
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

Review 4.  Antidepressant discontinuation syndrome.

Authors:  Christopher H Warner; William Bobo; Carolynn Warner; Sara Reid; James Rachal
Journal:  Am Fam Physician       Date:  2006-08-01       Impact factor: 3.292

5.  Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.

Authors:  E C G van Geffen; J G Hugtenburg; E R Heerdink; R P van Hulten; A C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2005-05-20       Impact factor: 2.953

6.  Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?

Authors:  P M Haddad; B R Pal; P Clarke; A Wieck; S Sridhiran
Journal:  J Psychopharmacol       Date:  2005-09       Impact factor: 4.153

7.  [Taperingstrips for paroxetine and venlafaxine].

Authors:  P C Groot
Journal:  Tijdschr Psychiatr       Date:  2013

8.  The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.

Authors:  Aung Tint; Peter M Haddad; Ian M Anderson
Journal:  J Psychopharmacol       Date:  2008-05       Impact factor: 4.153

9.  Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.

Authors:  Megan Galbally; Andrew J Lewis; Jarrad Lum; Anne Buist
Journal:  Aust N Z J Psychiatry       Date:  2009-09       Impact factor: 5.744

Review 10.  Agomelatine in depression.

Authors:  Enrico Smeraldi; Dario Delmonte
Journal:  Expert Opin Drug Saf       Date:  2013-09-16       Impact factor: 4.250

View more
  22 in total

Review 1.  [General treatment principles, coordination of care and patient education in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  F Petzke; W Brückle; U Eidmann; P Heldmann; V Köllner; T Kühn; H Kühn-Becker; M Strunk-Richter; M Schiltenwolf; M Settan; M von Wachter; M Weigl; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

2.  Recognition and management of antidepressant discontinuation syndrome.

Authors:  Venkat Bhat; Sidney H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2017-06       Impact factor: 6.186

3.  Managing Antidepressant Discontinuation: A Systematic Review.

Authors:  Emma Maund; Beth Stuart; Michael Moore; Christopher Dowrick; Adam W A Geraghty; Sarah Dawson; Tony Kendrick
Journal:  Ann Fam Med       Date:  2019-01       Impact factor: 5.166

4.  Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?

Authors:  Jennifer Severe; John F Greden; Priyanka Reddy
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

Review 5.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

6.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

7.  Trends in GP prescribing of psychotropic medications among young patients aged 16-24 years: a case study analysis.

Authors:  Bianca Brijnath; Ting Xia; Lyle Turner; Danielle Mazza
Journal:  BMC Psychiatry       Date:  2017-06-06       Impact factor: 3.630

8.  Management of Tizanidine Withdrawal Syndrome: A Case Report.

Authors:  A Suárez-Lledó; A Padullés; T Lozano; S Cobo-Sacristán; M Colls; R Jódar
Journal:  Clin Med Insights Case Rep       Date:  2018-02-13

9.  The depressive-like behaviors of chronic unpredictable mild stress-treated mice, ameliorated by Tibetan medicine Zuotai: involvement in the hypothalamic-pituitary-adrenal (HPA) axis pathway.

Authors:  Jing Zhao; Cuiying Niu; Jianv Wang; Hongxia Yang; Yuzhi Du; Lixin Wei; Cen Li
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-03       Impact factor: 2.570

10.  Is There a Potential of Misuse for Venlafaxine and Bupropion?

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  Front Pharmacol       Date:  2018-03-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.